High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Abstract: Of the 27 viraemic isolates successfully genotyped, 20 (74.1%) carried DR mutations; most frequent were M184VI (55.6%), K103N (37.1%), thymidine analog mutations (29.6%), Y181CY (22.2%).
Result: For NRTIs, these were M184VI (55.6%), T215SNY (22.2%), and K65R (18.5%).
Reverse transcriptase and protease inhibitors mutational viral load in HIV infected pregnant women with transmitted drug resistance in Argentina.
PMID: 34085506
2021
Revista espanola de quimioterapia
Abstract: The following NRTI RAMs were described (per patient: % of quasispecies, ML): T215I (99.7%, 11014 c/ml); D67G (1.28%, 502 c/mL); M41L (79.8%, 88578 c/mL) and M184I (1.02%, 173 c/mL).
Discussion: M184I/V was infrequent in naive pregnant women.
Discussion: Therefore, updated local studies evaluating prevalence of M184I/V mutations in general population are needed.
High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.
Abstract: The DRMs most frequent were M184I/V (82.9%) for nucleoside reverse transcriptase inhibitors (NRTI), K103N/S (63.4%) for nonnucleoside reverse transcriptase inhibitor (NNRTI), and V82A/L/M (7.3%) for protease inhibitors (PI).
Result: High resistance level to NRTI class was verified in 85.3% (n = 70/82), being most of them 82.9% (n = 68/82) among those under 3TC use, and the M184I/V mutation was presented in all of them.
Result: The most frequently detected DRMs were M184I/V (68/82; 82.9%),
Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.
PMID: 34189182
2021
Open forum infectious diseases
Introduction: BIC/FTC/TAF has also been proven efficacious in sustaining viral suppression in individuals with documented M184V/I mutations.
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naive and treatment-experienced patients with human immunodeficiency virus-1 infection.
PMID: 32715952
2020
HIV research & clinical practice
Abstract: Among 3317 patients using nucleos(t)ide reverse transcriptase inhibitors (N[t]RTIs; mostly emtricitabine and tenofovir), 13 (0.4%) had >=1 N(t)RTI RAM (10 with M184I/V).
Abstract: Among patients receiving D/C/F/TAF (n = 1949), none had post-baseline darunavir, primary PI, or tenofovir RAMs; only two (0.1%) patients developed an emtricitabine RAM, M184V/I.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 32737511
2020
The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Among virally suppressed PLWH, EVG/C/FTC/TAF is effective in maintaining viral suppression at Week 48 despite archived M184V/I mutation with or without TAMs.
Abstract: OBJECTIVES: Real-world experience regarding the effectiveness of co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/C/FTC/TAF) as a switch regimen is sparse among people living with HIV (PLWH) harbouring the M184V/I mutation with or without thymidine analogue-associated mutations (TAMs).
Abstract: Patients with archived M184V/I mutation (case patients) were matched to controls without M184V/I mutation at a 1:4 ratio.
Abstract: RESULTS: Overall, 100 case patients with the M184V/I mutation were identified, including 6 (6.0%) with PMID: 32925358
2020
Journal of acquired immune deficiency syndromes (1999)
Method: The participant in the baseline group who received ritonavir-boosted darunavir, FTC, and TDF displayed an RT M184M/I substitution.
Table: M184I
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Abstract: Further studies are needed to determine optimal antiretroviral therapy for patients with the M184V/I mutation.
Abstract: Methods: A retrospective chart review was conducted of 100 treatment-experienced patients harboring the M184V/I mutation seen at an urban HIV clinic.
Abstract: Objectives: The optimal antiretroviral therapy for patients with the M184V/I mutation is not known.
Abstract: Regimens containing less than 3 active agents may maintain virologic suppression in patients with the M184V/I mutation.
Abstract: The primary objective of this study was to determine the efficacy of various antiretroviral therapies in patients with HIV and the M184V/I mutation based on the number of active antiretroviral agents.
Result: One hundred patients wit
Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
PMID: 33654530
2020
The Pan African medical journal
Table: M184I
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Discussion: Furthermore, TAF exhibits still full efficacy in the presence of the M184V/I mutation in contrast to ABC.
Discussion: Given that TDF/TAF still exhibits full efficacy in the presence of the M184V/I mutation, this backbone component should be preferred in combination with DTG in low:and middle-income countries.
Discussion: Patients with the M184V/I mutation had a lower
Discussion: Thirdly, the patient harbored the M184V/I mutation, which causes reduced susceptibility to two (3TC, ABC) out of the three components of the DTG/3TC/ABC regimen.
Discussion: This is a rare case of a patient with pre-existing M184V/I mutation and virological failure on a DTG/3TC/ABC regimen with the emergence of INSTI resistance mutations.
HIV mutation literature information.
PMID: 
2021
Infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT